Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552231194077 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Marta Albanell-Fernández und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Carboplatin, Antiemetics, Nausea, Dexamethasone. Die Arbeit nennt 34 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Chemotherapy-induced nausea and vomiting (CINV) is one of the adverse events that most affects oncologic patients’ quality of life. Carboplatin AUC ≥ 4 belongs to agents with high emetic risk (moderate risk in ASCO guidelines). We aimed to compare the effectiveness of netupitant/palonosetron and dexamethasone triple combination (TC) therapy versus ondansetron and dexamethasone double combination (DC) therapy as antiemetic prophylaxis in patients with carboplatin AUC ≥ 4. As a secondary endpoint, in TC group we evaluated the effectiveness of changing NEPA administration timing from 1 h to 15 min before chemotherapy.
Methods
Open-label prospective study conducted in a tertiary-care hospital in patients receiving carboplatin AUC ≥ 4. CINV was evaluated using MASCC antiemetic tool, in acute (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain.
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain.
ORCID-Profile: Marta Albanell-Fernández, Gisela Riu-Viladoms
Zitieren
APA
Albanell-Fernández, M., Pérez Sánchez, Á., Monge-Escartín, I., Riu-Viladoms, G., Rodríguez Mues, M. C., Corominas Bosch, M. L., Gaba García, L., Rollán, N. B., Reguart, N., Soy Muner, D., & Carcelero San Martín, E. (2024). Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231194077
Vancouver
Albanell-Fernández M, Pérez Sánchez Á, Monge-Escartín I, Riu-Viladoms G, Rodríguez Mues MC, Corominas Bosch ML, et al. Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231194077
BibTeX
@article{AlbanellFernndez2024,
author = {Albanell-Fernández, Marta and Pérez Sánchez, Ángela and Monge-Escartín, Inés and Riu-Viladoms, Gisela and Rodríguez Mues, Mª Carmen and Corominas Bosch, Mª Lourdes and Gaba García, Lydia and Rollán, Neus Basté and Reguart, Noemí and Soy Muner, Dolors and Carcelero San Martín, Esther},
title = {Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552231194077}
}
EUVIMED